市場調查報告書
商品編碼
1423572
全球胰島素輸送設備市場預測(-2030):按產品、分銷管道、最終用戶和地區分析Insulin Delivery Devices Market Forecasts to 2030 - Global Analysis By Product (Insulin Pumps, Insulin Pens, Insulin Pen Needles, Insulin Syringes, Insulin Inhalers, Insulin Jet Injectors & Other Types), Distribution Channel, End User & By Geography |
2023年,全球胰島素輸送設備市場規模為149億美元,預計預測期內複合年成長率為9.4%,到2030年將達280億美元。
胰島素輸送裝置是設計用於向糖尿病患者施用胰島素的工具或系統。它用於透過將胰島素泵入體內來調節血糖值。這些設備有型態,包括胰島素注射器、胰島素筆針、胰島素幫浦和胰島素噴射注射器。這些設備提供了多種胰島素給藥方法,使個人能夠根據自己的生活方式、偏好和胰島素需求更有效地管理自己的病情。
根據國際糖尿病聯盟(IDF)的數據,2021年約有5.37億成年人患有糖尿病,預計到2030年這一數字將增加6.43億。
糖尿病盛行率上升
糖尿病盛行率的不斷上升正在推動胰島素輸送設備的進步。科技創新滿足多元需求,提供便利精準。從傳統的注射器到先進的胰島素幫浦和筆,技術徹底改變了管理。智慧型設備整合了監測和交付,增加了患者的自主權。這些設備代表了糖尿病照護的重大進步,不僅提高了糖尿病患者的醫囑遵從性,還提高了他們的生活品質。
技術問題
胰島素輸送設備可能會出現影響胰島素給藥的技術故障。故障可能會導致胰島素給藥不正確,從而導致高血糖或低血糖。機械故障,例如針頭堵塞或幫浦堵塞,需要即時更換,並可能導致胰島素治療的不便或中斷。這些技術缺陷凸顯了使用者保持警覺和定期設備檢查的重要性,以確保無縫和安全的胰島素輸送。這些都是限制市場成長的因素。
採取促銷舉措
胰島素輸送設備的加速舉措徹底改變了糖尿病治療。智慧泵、連續血糖監測整合和方便用戶使用介面等先進技術簡化了管理。此外,自動胰島素輸送演算法等技術主導的功能可提供精確、即時的調整。擁抱這些創新不僅可以增強患者的能力,還可以促進醫療保健提供者和糖尿病患者之間的協作。這些都是推動市場成長的因素。
高成本
胰島素輸送設備的高價格帶來了顯著的缺點,主要影響了糖尿病患者的可得性和購買能力。這種經濟負擔往往限制了獲得基本設備的機會,導致護理不足或不一致。缺乏財政資源可能會阻礙對血糖值的持續監測和有效的胰島素管理,從而導致不良的健康結果。這些點限制了市場的成長。
製造業放緩、運輸問題和醫療用品需求增加導致某些設備間歇性短缺和供應延遲。此次疫情凸顯了設備消毒和安全措施的重要性。製造商和使用者更加重視確保胰島素輸送裝置得到適當的清洗和維護,以最大限度地降低感染風險。
預計在預測期內胰島素筆針細分市場將是最大的
在預測期內,胰島素筆針市場預計將是最大的。其高採用率、方便用戶使用的設計以及不斷成長的消費者吸引力是該細分市場擁有最高銷售佔有率的一些因素。高市場佔有率的一個主要貢獻者是製造商對創新和進步的日益關注。因此,產品創新預計將在不久的將來推動胰島素筆針的需求。
居家照護產業預計在預測期內複合年成長率最高
由於人們對糖尿病護理的認知不斷提高,預計居家照護領域在預測期內將出現最高的複合年成長率。在家使用胰島素裝置可減少等待時間、醫院和診所費用以及就診費用。筆、注射器和泵等尖端產品結構緊湊、便於攜帶且始終有用。由於可用性和可及性的提高,胰島素使用者擴大選擇自我護理糖尿病管理解決方案。
預計北美在預測期內將佔據最大的市場佔有率。由於糖尿病盛行率增加、胰島素輸送系統技術進步以及人口老化不斷加劇等多種因素,該地區的市場正在顯著成長。此外,醫療保健提供者、製造商和研究機構之間合作開發創新的胰島素輸送設備正在進一步推動該地區的市場成長。
預計亞太地區在預測期內將維持最高的複合年成長率。由於各種因素,包括糖尿病盛行率上升、對先進胰島素輸送技術的認知不斷提高以及一些國家醫療基礎設施的改善,該地區的市場正在顯著成長。此外,政府促進糖尿病管理和胰島素輸送系統技術進步的措施也有助於市場擴張。
According to Stratistics MRC, the Global Insulin Delivery Devices Market is accounted for $14.9 billion in 2023 and is expected to reach $28.0 billion by 2030 growing at a CAGR of 9.4% during the forecast period. Insulin delivery devices are tools or systems designed to administer insulin to individuals with diabetes. They're used to regulate blood sugar levels by delivering insulin into the body. These devices come in various forms, such as insulin syringes, insulin pens, insulin pumps, and insulin jet injectors. They provide different methods for insulin administration, allowing individuals to manage their condition more effectively based on their lifestyle, preferences, and insulin needs.
According to International Diabetes Federation (IDF), the adult diabetes population in 2021 was approximately 537 million, and this number is expected to increase by 643 million in 2030.
Rising prevalence of diabetes
The rising prevalence of diabetes has fuelled advancements in insulin delivery devices. Innovations cater to diverse needs, offering convenience and precision. From traditional syringes to advanced insulin pumps and pens, technology has revolutionized management. Smart devices integrate monitoring with delivery, enhancing patient autonomy. These devices not only improve adherence but also enhance quality of life for individuals managing diabetes, marking a significant stride in diabetes care.
Technical issues
Insulin delivery devices can encounter technical glitches impacting insulin administration. Malfunctions pose risks of incorrect insulin delivery, leading to hyper or hypoglycemia. Mechanical failures, like needle jams or pump blockages, necessitate immediate replacement, potentially causing inconvenience or interruptions in insulin therapy. These technical drawbacks highlight the importance of user vigilance and regular device checks to ensure seamless and safe insulin delivery. These are the factors restraining the growth of the market.
Adoption of facilitative initiatives
Facilitative initiatives in insulin delivery devices have revolutionized diabetic care. Advances like smart pumps, continuous glucose monitoring integration, and user-friendly interfaces streamline management. Additionally, tech-driven features, such as automated insulin delivery algorithms, offer precise, real-time adjustments. Embracing these innovations not only empowers patients but also fosters a collaborative approach between healthcare providers and individuals managing diabetes. These are the factors propelling the growth of the market.
High cost
The high cost of insulin delivery devices poses significant disadvantages, primarily affecting accessibility and affordability for individuals managing diabetes. This financial burden often restricts access to essential equipment, leading to inadequate or inconsistent treatment. Limited affordability can result in compromised health outcomes due to the inability to consistently monitor blood sugar levels or administer insulin effectively. These are the aspects limiting the growth of the market.
Manufacturing slowdowns, transportation issues, and increased demand for medical supplies led to intermittent shortages and delays in availability for certain devices. The pandemic emphasized the importance of device sanitization and safety measures. Manufacturers and users paid more attention to ensuring that insulin delivery devices were properly cleaned and maintained to minimize the risk of infection.
The insulin pens segment is expected to be the largest during the forecast period
The insulin pens segment is expected to be the largest during the forecast period. ts advantages over other products. Its high adoption rate, user-friendly design, and growing consumer appeal were some of the factors that led to this segment's highest revenue share. A significant contributing aspect to the high share is the increasing emphasis that manufacturers are placing on innovation and advances. Therefore, it is anticipated that in the near future, product innovations will drive the demand for insulin pens.
The home care segment is expected to have the highest CAGR during the forecast period
The home care segment is expected to have the highest CAGR during the forecast period due to increasing awareness of diabetes care. Insulin devices used at home reduce waiting times, hospital or clinic fees, and visitation expenses. The cutting-edge gadgets, which come in the form of pens, injectors, and pumps, are compact, extremely portable, and always useful. Because of their increased usability and increased accessibility, insulin users are choosing self-care diabetes control solutions.
North America is projected to hold the largest market share during the forecast period. The market in the region has been significant, driven by various factors such as the increasing prevalence of diabetes, technological advancements in insulin delivery systems, and the growing aging population. Additionally, collaborations between healthcare providers, manufacturers, and research institutions for developing innovative insulin delivery devices have further propelled market growth in the region.
Asia Pacific is projected to hold the highest CAGR over the forecast period. The market in the region has been witnessing significant growth due to various factors such as the rising prevalence of diabetes, increasing awareness about advanced insulin delivery technologies, and improving healthcare infrastructure in several countries. Moreover, government initiatives promoting diabetes management and technological advancements in insulin delivery systems contribute to the market's expansion.
Key players in the market
Some of the key players in Insulin Delivery Devices market include Abbott Laboratories, Novo Nordisk A/S, Wockhardt Ltd., Medtronic, F. Hoffmann-La Roche, Ltd., Becton, Dickinson and Company, Sanofi, Eli Lilly and Company, Biocon Ltd., Roche, Insulet Corporation, B Braun Melsungen AG, Tandem Diabetes Care, Embecta Corporation and Ypsomed AG.
In June 2023, Novo Nordisk entered negotiations of acquiring BIOCORP, which specialized in the design and development of medical devices. This was done for the development of FlexTouch Pen with Mallya, an add-on Bluetooth device.
In Feb 2023, Lilly and IABL, the largest healthcare provider collaborated to provide high-quality and affordable insulin in Bangladesh.